You are here

Article Text

Article menu
Download PDFPDF
Endoscopy
Original research
Clinical spectrum of paediatric and adult eosinophilic oesophagitis in the North East of England from 2016 to 2019
  1. Ben Shillitoe1,
  2. Ji Ching Lee2,
  3. Mohammed Hussien3,
  4. Iosif Beintaris3,
  5. Mark Stothard2,
  6. Matthew Johnston2,
  7. Helen Jane Dallal2,
  8. Louise J Michaelis1,4,
  9. Stephen Attwood5,
  10. Anjan Dhar2,6
  1. 1 Paediatric Immunology, Allergy and Infectious DIseases, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
  2. 2 Gastroenterology, County Durham and Darlington NHS Foundation Trust, Durham, UK
  3. 3 Gastroenterology, North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, UK
  4. 4 Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK
  5. 5 Population Health Sciences, Durham University, Durham, UK
  6. 6 School of Health and Life Sciences, Teesside University, Middlesbrough, UK
  1. Correspondence to Dr Ben Shillitoe, Paediatric Immunology, Allergy and Infectious DIseases, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne NE1 4LP, UK; benjamin.shillitoe{at}nhs.net

Abstract

Background and study aims Eosinophilic oesophagitis (EoE) is a common disease with a significant impact on physical health and quality of life (QoL). Outcomes and management vary widely, with no agreed UK national guideline. This paper aims to describe an up-to-date description of demographics, clinical spectrum and outcomes for paediatric and adult patients with EoE from the North East of England between 2016 and 2019.

Patients and methods Patients from two large University Hospitals and the specialist paediatric hospital for the North East of England with histologically or clinically confirmed EoE were included in this analysis. Data were collected retrospectively via electronic patient records. Remission was defined as either the resolution of symptoms or improvement on histology.

Results Data were collected on 74 paediatric and 59 adult patients. Dysphagia was the most common presenting symptom in both groups, accounting for 51%–84% of all presentations. Proton pump inhibitors and dietary manipulation were the most common therapies associated with remission in children (95% of those achieving remission), whereas the use of swallowed topical steroids was more prevalent in the treatment of adults (55% achieving remission).

Conclusions EoE is a complex disease and poses significant challenges. Outcomes vary widely and need to be tailored to individual patient groups. Dietary manipulation plays a major role in treatment for EoE, but this is likely to be challenging for patients, especially children. Future work should continue to assess the outcomes in EoE, including on QoL and potential novel targeted therapies.

  • oesophageal disease
  • paediatric gastroenterology
  • allergy
  • endoscopy
  • oesophagitis

Data availability statement

All data relevant to the study are included in the article or uploaded as supplemental information.

https://doi.org/10.1136/flgastro-2021-101814

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    All data relevant to the study are included in the article or uploaded as supplemental information.

    View Full Text

    Footnotes

    • BS and JCL are joint first authors.

    • Twitter @iosifbeintaris, @anjan_dhar6

    • Correction notice This article has been corrected since it published Online First. The ORCID ID has been added for Louise Michaelis.

    • Contributors BS and JCL collected and analysed all data and drafted the manuscript. LJM, SA and AD conceived the idea for the study, provided overall supervision of the project and gave substantial editorial oversight to the manuscript. MH, IB, MS, MJ, HJD provided clinical data to the study and provided feedback to the data analysis and manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.